Bogers H A, Sedelaar J P, Beerlage H P, de la Rosette J J, Debruyne F M, Wijkstra H, Aarnink R G
Department of Urology, University Hospital Nijmegen, The Netherlands.
Urology. 1999 Jul;54(1):97-104. doi: 10.1016/s0090-4295(99)00040-0.
To determine the feasibility of contrast-enhanced three-dimensional (3D) imaging of the prostatic vasculature using power Doppler imaging and to analyze whether semiquantitative judgments of 3D images with respect to symmetry and distribution of vascular structures correlated with biopsy outcome.
3D power Doppler images were obtained before and after intravenous administration of 2.5 g Levovist. Subsequently, random and/or directed transrectal ultrasound (TRUS)-guided biopsies were performed. Vascular images were analyzed by two experts. Prostate vasculature was judged with respect to symmetry and vessel distribution using a (scale) grading system.
Eighteen patients with a suspicion of prostate cancer either because of an elevated prostate-specific antigen (greater than 4.0 ng/mL; Tandem-R-assay) or an abnormal digital rectal examination were included in the study. Prostate cancer was detected in 13 patients. Vascular anatomy was judged abnormal in unenhanced images in 6 cases, of which 5 proved malignant. Enhanced images were considered suspicious for malignancy in 12 cases, including 1 benign and 11 malignant biopsy results. Sensitivity of enhanced images was 85% (specificity 80%) compared with 38% for unenhanced images (specificity 80%) and 77% for conventional gray-scale TRUS (specificity 60%). Of 6 patients who showed no B-mode abnormalities, vascular patterns were judged abnormal in 4 cases, of which 3 were malignant.
Contrast-enhanced 3D power Doppler angiography is feasible in patients with suspicion of prostate cancer who are scheduled for prostate biopsies. The sensitivity of power Doppler 3D imaging for the detection of prostate malignancy increased from 38% (5 of 13) to 85% (11 of 13) after administration of intravascular microbubble contrast (Levovist), and specificity was found to be 80% (4 of 5) for both imaging modalities. Thus, the use of Levovist when combined with the power Doppler display mode and 3D image reconstruction offers a promising new research area that might prove useful in prostate cancer detection in the future.
使用能量多普勒成像确定前列腺血管造影增强三维(3D)成像的可行性,并分析关于血管结构对称性和分布的3D图像半定量判断是否与活检结果相关。
静脉注射2.5g Levovist前后获取3D能量多普勒图像。随后,进行随机和/或经直肠超声(TRUS)引导下的活检。两名专家对血管图像进行分析。使用(量表)分级系统对前列腺血管进行对称性和血管分布方面的判断。
18例因前列腺特异性抗原升高(大于4.0 ng/mL;Tandem-R检测法)或直肠指检异常而怀疑患有前列腺癌的患者纳入本研究。13例患者检测出前列腺癌。6例未增强图像的血管解剖结构被判定异常,其中5例为恶性。12例增强图像被认为有恶性可疑,包括1例良性和11例恶性活检结果。增强图像的敏感性为85%(特异性80%),未增强图像为38%(特异性80%),传统灰阶TRUS为77%(特异性60%)。6例B模式无异常的患者中,4例血管模式被判定异常,其中3例为恶性。
对于计划进行前列腺活检且怀疑患有前列腺癌的患者,造影增强三维能量多普勒血管造影是可行的。血管内微泡造影剂(Levovist)注入后,能量多普勒3D成像检测前列腺恶性肿瘤的敏感性从38%(13例中的5例)提高到85%(13例中的11例),两种成像方式的特异性均为80%(5例中的4例)。因此,Levovist与能量多普勒显示模式及3D图像重建结合使用,提供了一个有前景的新研究领域,未来可能在前列腺癌检测中发挥作用。